Fresenius Kabi Enters Marketing Agreement With Germany's Medac
May 28 2020 - 3:22AM
Dow Jones News
By Olivia Bugault
Fresenius SE & Co. said Thursday that its Kabi unit and
German pharmaceutical company medac have entered into a marketing
agreement for treatments of rheumatic illnesses.
"On June 1, medac's sales representatives will begin offering
the adalimumab biosimilar IDACIO(R) as an additional therapy option
to the rheumatologists and dermatologists they work with," the
German health-care company said.
The product developed by Fresenius Kabi was launched in Europe
in 2019 for the treatment of illnesses such as arthritis and
psoriasis, it said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
May 28, 2020 03:07 ET (07:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Fresenius SE & Co KGaA (TG:FRE)
Historical Stock Chart
From Apr 2024 to May 2024
Fresenius SE & Co KGaA (TG:FRE)
Historical Stock Chart
From May 2023 to May 2024